Terconazole

SKU: orb1224268

Description

Arecoline is a muscarinic acetylcholine receptor agonist. Arecoline induces ADP ribosylation of histones and chromatid relaxation in spleen and bone marrow cells.(In Vitro):Terconazole inhibits the growth of Candida albicans ATCC 44859 in a concentration-related manner, but with modest effects noted at levels from 0.1 to 10 μM when the yeast is grown on media favoring the cell form. The inhibitory potency of terconazole on yeast cell viability varies with the strain and species of Candida tested. The susceptibility of C. albicans ATCC 44859 to terconazole is markedly enhanced when the yeast is grown on Eagle minimum essential medium, which favors mycelium formation. There is a progression of changes, from loss of mycelia formation at 0.1 μM terconazole through complete necrosis at 100 μM. Terconazole blocks the morphogenetic transformation from the yeast into the filamentous form at concentrations of 0.008 to 0.05 microgram/mL.(In Vivo):A 3-day once-daily intravaginal application of terconazole 0.8% is usually sufficient to provide a functional therapeutic period of 7 days because of prolonged high biologically active antifungal levels in the vagina. No side effects are observed at any concentration of terconazole.

Key Properties

• CAS Number: 67915-31-5
• MW: 532.46
• Purity: >98% (HPLC)
• Formula: C₂₆H₃₁Cl₂N₅O₃
• SMILES: CC(N1CCN(C2=CC=C(OC[C@H]3O[C@](CN4N=CN=C4)(C5=CC=C(Cl)C=C5Cl)OC3)C=C2)CC1)C
• Target: Antifection
• Solubility: Soluble in DMSO

Bioactivity

• In Vivo:
  A 3-day once daily intravaginal application of terconazole 0.8% is usually sufficient to provide a functional therapeutic period of 7 days because of prolonged high biologically active antifungal levels in the vagina. No side effects are observed at any concentration of terconazole.
• In Vitro:
  Terconazole inhibits the growth of Candida albicans ATCC 44859 in a concentration-related manner, but with modest effects noted at levels from 0.1 to 10 μM when the yeast is grown on media favoring the cell form. The inhibitory potency of terconazole on yeast cell viability varies with the strain and species of Candida tested. The susceptibility of C. albicans ATCC 44859 to terconazole is markedly enhanced when the yeast is grown on Eagle minimum essential medium, which favors mycelium formation. There is a progression of changes, from loss of mycelia formation at 0.1 μM terconazole through complete necrosis at 100 μM. Terconazole blocks the morphogenetic transformation from the yeast into the filamentous form at concentrations of 0.008 to 0.05 microgram/mL.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

NSC 331942 | R-42470 | (±)-Terconazole

Quick Database Links

Gene Symbol

Antifection